Skip to main content

Feraheme FDA Approval History

FDA Approved: Yes (First approved June 30, 2009)
Brand name: Feraheme
Generic name: ferumoxytol
Dosage form: Intravenous Injection
Company: AMAG Pharmaceuticals, Inc.
Treatment for: Anemia Due to Chronic Kidney Disease, Iron Deficiency Anemia

Feraheme (ferumoxytol) is an iron replacement therapy for the treatment of iron deficiency anemia in adult patients.

Development timeline for Feraheme

DateArticle
Feb  5, 2018Approval AMAG Pharmaceuticals Announces FDA Approval of Feraheme (ferumoxytol injection) for All Eligible Adult Patients with Iron Deficiency Anemia
Jun 30, 2009Approval FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients
May 12, 2009AMAG Pharmaceuticals Announces New PDUFA Date for Feraheme (ferumoxytol injection)
Dec 23, 2008AMAG Pharmaceuticals Receives Complete Response Letter from the FDA for Ferumoxytol
Nov 13, 2008AMAG Pharmaceuticals Announces Ferumoxytol Resubmission Designated Complete, Class 1 Response by the FDA
Oct 20, 2008AMAG Pharmaceuticals Receives Complete Response Letter from FDA for Ferumoxytol
Feb 19, 2008AMAG Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Ferumoxytol New Drug Application in Chronic Kidney Disease
Dec 19, 2007AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients

See also

Feraheme (ferumoxytol) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer